Brickworks Limited (ASX:BKW) Increases Interim Dividend and Reports Strong Earnings Growth
Brickworks Limited (ASX:BKW) announces an increased interim dividend and significant growth in underlying earnings for the first half of FY2025.
Golden Cross Resources (ASX:GCR) Completes Copper Hill Gravity Survey
Golden Cross Resources (ASX:GCR) completes a gravity survey at Copper Hill Tenement, enhancing exploration for copper-gold mineralisation.
Dreadnought Resources Ltd (ASX:DRE) Consolidates Further Gold Ground at Mangaroon
Dreadnought Resources (ASX:DRE) expands Mangaroon Gold Project by acquiring E09/2479, enhancing gold exploration prospects.
Strategic Energy Resources (ASX:SER) Secures Bulimba Gold Project
Strategic Energy Resources (ASX:SER) secures the Bulimba Gold Project in NE Queensland, targeting significant gold deposits.
Prospect Resources Limited (ASX:PSC) Identifies High-Priority Drill Target at Nyungu South
Prospect Resources (ASX:PSC) identifies a high-priority drill target at Nyungu South, enhancing exploration prospects at the Mumbezhi Copper Project.
Artemis Resources (ASX:ARV) Completes Phase One Drilling at Carlow Tenement
Artemis Resources (ASX:ARV) completes initial drilling phase at Carlow Tenement, testing high-priority gold targets with promising geological findings.
Qoria (ASX:QOR) Secures Strategic Partnership with Ohio Education Council
Qoria (ASX:QOR) secures a strategic partnership with Ohio Education Computer Network to enhance student safety and wellbeing services statewide.
Rhythm Biosciences Ltd (ASX:RHY) Records First Commercial Sales of geneType Products
Rhythm Biosciences (ASX:RHY) records its first commercial sales of geneType products, anticipating growth throughout the year.
C29 Metals (ASX:C29) Expands Ulytau Project with New Exploration Licence
C29 Metals (ASX:C29) secures a new exploration licence, expanding the Ulytau Project footprint by 116 km² in Kazakhstan.
Imugene Limited (ASX:IMU) Granted FDA Fast Track Designation for Azer-cel
Imugene Limited (ASX:IMU) secures FDA Fast Track designation for its allogeneic CAR T-cell therapy azer-cel, advancing treatment for relapsed or refractory diffuse large B-cell lymphoma.